Barclays Maintains Overweight on Travere Therapeutics, Raises Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould maintains an Overweight rating on Travere Therapeutics (NASDAQ:TVTX) and raises the price target from $12 to $14.
August 02, 2024 | 2:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays analyst Carter Gould maintains an Overweight rating on Travere Therapeutics and raises the price target from $12 to $14.
The Overweight rating and increased price target from a reputable analyst at Barclays is likely to positively influence investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100